GlaxoSmithKline PLC — Director's Dealing 2019

Feb 19, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5148Q

GlaxoSmithKline PLC

19 February 2019

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Transfer of 102,035 Ordinary Shares between accounts for nil consideration.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.00	102,035
d)	Aggregated information	n/a (single transaction)
Aggregated volume Price
e)	Date of the transaction	2019-02-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Transfer of 102,035 Ordinary Shares to spouse for nil consideration. No change in beneficial ownership.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.00	102,035
d)	Aggregated information	n/a (single transaction)
Aggregated volume Price
e)	Date of the transaction	2019-02-18
f)	Place of the transaction	n/a

	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr David Owen
b)	Position/status	PCA of Ms E Walmsley (Chief Executive Officer)
c)	Initial notification/ amendment	Initial Notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Receipt of 102,035 Ordinary Shares from spouse for nil consideration.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	£0.00	102,035
d)	Aggregated information	n/a (single transaction)
Aggregated volume Price
e)	Date of the transaction	2019-02-18
f)	Place of the transaction	n/a

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHZKLFFKLFLBBB